摘要
目的探讨弥可保联合七叶皂苷钠治疗急性特发性面神经麻痹的有效性与安全性。方法选择2007年6月-2009年12月首次发病诊断的急性特发性面神经麻痹患者98例，并随机分为观察组49例（弥可保联合七叶皂苷钠加基础治疗），对照组49例（强的松联合基础治疗），基础治疗包括多种维生素、抗病毒治疗、针灸、理疗等。结果观察组痊愈率为53．06％，总有效率为95．92％。对照组痊愈率为24．49％，总有效率为81．63％，两组相比差异有显著性（P〈0．05）。结论弥可保联合七叶皂苷钠治疗急性特发性面神经麻痹能使受损的面神经早日康复，有效改善其预后，且无不良反应。
Objective To explore the availability and the safety of Methycobal union sodium aescinate treatment for acute idiopathic facial palsy. Methods 98 cases with acute idiopathic facial palsy in the first diagnosis were chosen from June 2007 to December 2009, and randomly and averagely divided into observation group（Methycobal union sodium aescinate with the basic treatment ） and control group（metacortandracin joint the foundation treatment ）. The foundation treatment included vitamins and antiviral therapy, acupuncture, medical treatment, etc. Results The cured rate in observation group was 53.06%, total effective rate was 95.92%. The cured rate in control group was 24.49%, total effective rate was 81.63%. There was significant difference between the 2 groups＇ results（ P〈 0.05 ）. Conclusion Methycobal union sodium aescinate treatment for acute idiopathic facial palsy can make the facial nerve fine, and improve its prognosis, and have no adverse effect.
出处
《国际医药卫生导报》
2011年第16期2011-2013,共3页
International Medicine and Health Guidance News
